查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884032

頭孢菌素市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032 年）

Cephalosporin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 請詢問到貨日

價格

頭孢菌素市場成長驅動因子

全球頭孢菌素市場持續保持強勁成長勢頭，主要受抗菌藥物抗藥性加劇、新產品核准以及對廣譜抗生素需求不斷增長的推動。 2024 年，該市場規模預計將達到 79.3 億美元，這主要得益於第三代和第四代頭孢菌素在呼吸道感染、皮膚感染、腦膜炎和醫院獲得性細菌感染治療中的廣泛應用。由於在醫院和門診環境中的應用日益廣泛，預計到 2025 年，市場規模將增長至 83.2 億美元。到 2032 年，全球市場規模預計將達到 120.7 億美元，這主要得益於抗菌素抗藥性病例的增加、先進製劑審批速度的加速以及對下一代抗生素研發的投資。

2024 年，北美市場佔主導地位，市佔率高達 46.78%，主要得益於高感染率、完善的醫院基礎設施以及新型頭孢菌素類藥物的積極推廣。

市場驅動因素

推動市場成長的關鍵因素是抗生素抗藥性細菌的日益普遍，這正在推動對新一代頭孢菌素的需求。葛蘭素史克（GSK plc）、輝瑞（Pfizer Inc.）、山德士（Sandoz Group AG）和默克（Merck & Co.）等製藥公司正在加強研發力度，以推出能夠對抗抗藥性菌株的創新療法。新核准的藥物，例如巴塞爾製藥（Basilea Pharmaceutica）的ZEVTERA（於2024年4月獲得美國FDA批准），透過為成人和兒童患者的菌血症、急性細菌性深部軟組織感染（ABSSSI）和肺炎提供治療選擇，進一步擴大了市場。

頭孢菌素類抗生素因其副作用少、抗菌譜廣、療效高，在全球傳染病控制中仍至關重要。

市場限制因子

儘管需求不斷增長，但與頭孢菌素使用相關的不良反應構成了市場挑戰。據報道，胃腸道疾病、過敏反應，甚至嚴重的神經毒性作用均有發生，尤其是在老年患者和接受高劑量靜脈給藥的患者身上。 2023年，紐西蘭藥品風險評估委員會 (MARC) 指出，靜脈注射頭孢菌素類藥物有腦病變、癲癇和肌陣攣的風險。這些擔憂促使高風險族群的處方受到限制，可能限制市場成長。

市場機會

基於奈米顆粒的藥物遞送系統的出現前景廣闊。研究表明，基於金奈米顆粒 (AuNPs) 和銀奈米顆粒的製劑可以恢復並增強傳統頭孢菌素類藥物的療效。這些奈米抗生素可以提高藥物療效、延長血漿半衰期並實現藥物的控釋。美國國立衛生研究院 (NIH) 於2023年發表的一項研究證實，低效頭孢菌素類藥物已成功轉化為高效奈米治療藥物，這為藥物創新提供了巨大的機會。

細分市場分析

代際分析

預計到2024年，第三代頭孢菌素將憑藉其治療腦膜炎、呼吸道感染和各種軟組織感染的能力，佔市場主導地位。第一代頭孢菌素仍廣泛用於治療非複雜性感染，而第二代藥物在呼吸道和耳鼻喉科感染方面保持穩定的需求。同時，為應對日益嚴峻的抗菌藥物抗藥性（AMR）挑戰，第四代和第五代藥物持續受到關注。

依給藥途徑

預計口服途徑將實現強勁增長，這得益於患者對自我給藥的偏好以及新藥的獲批，例如Fairdeal Co., Ltd.於2024年批准的頭孢克肟400mg片劑。

腸外給藥途徑同樣重要，特別適用於需要住院治療的嚴重感染。鹽野義製藥株式會社於2023年推出的Fetroja等新型靜脈注射產品的上市，進一步鞏固了這個細分市場。

依疾病分類

由於醫院獲得性尿路感染（UTI）病例的增加以及每一代頭孢菌素類抗生素在治療UTI方面的療效已得到證實，預計尿路感染細分市場將繼續保持領先地位。

其他主要細分市場，包括皮膚和軟組織感染、呼吸道感染和腦膜炎，也因其全球高發病率和廣泛的臨床應用而貢獻顯著。

依分銷管道分類

由於處方量大以及需要使用頭孢菌素治療急性感染，醫院藥局佔市場主導地位。零售藥房緊隨其後，這主要得益於口服製劑的廣泛可及性和價格優勢。由於便利性、成本效益以及數位醫療的日益普及，線上藥局正經歷著穩定成長。

區域展望

北美

預計到2024年，北美市場規模將達到37.1億美元，這主要得益於耐甲氧西林金黃色葡萄球菌（MRSA）感染病例的增加、醫療保健支出的增加以及先進頭孢菌素療法的快速普及。美國在區域市場中處於領先地位，這得益於持續的研發投入，包括羅氏計畫在2025年投資500億美元的擴張計畫。

歐洲

歐洲佔第二大市場佔有率，這主要得益於第二代和第三代頭孢菌素消費量的增長以及強有力的抗菌藥物管理舉措。

亞太地區

預計2025年至2032年，亞太地區將實現最高的複合年增長率，這主要得益於高抗生素消費量、強大的原料藥生產能力以及戰略收購，例如Hasten Biopharmaceuticals於2023年收購了頭孢菌素在中國的權益。

拉丁美洲、中東和非洲

預計這些地區將保持穩定成長，這得益於人們對抗菌素抗藥性（AMR）的認識不斷提高、醫療基礎設施的改善以及頭孢菌素生產獲得新的監管批准。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵洞察

  • 主要公司產品線分析
  • 抗菌藥物治療指引概述
  • 世衛組織抗藥性 "優先病原體" 概述
  • 主要產業趨勢（併購、合作等）
  • 主要公司新產品發布

第五章：全球頭孢菌素市場市場分析、洞察與預測 (2019-2032)

  • 按世代劃分的市場分析、洞察與預測
    • 第一代
    • 第二代
    • 第三代
    • 第四代
    • 其他
  • 依給藥途徑劃分的市場分析、洞察與預測
    • 口服
    • 腸外給藥
  • 依疾病劃分的市場分析、洞察與預測
    • 泌尿道感染
    • 皮膚和軟組織感染
    • 呼吸道感染
    • 腦膜炎
    • 其他
  • 依銷售管道劃分的市場分析、洞察與預測
    • 醫院藥房
    • 零售藥房
    • 線上通路藥房
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美頭孢菌素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲頭孢菌素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 其他國家/地區歐洲

第八章 亞太地區頭孢菌素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲頭孢菌素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東與非洲頭孢菌素市場分析、洞察與預測2019-2032

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
    • 輝瑞公司
    • 山德士集團
    • 默克公司
    • 艾伯維公司
    • 拜耳公司
    • 安斯泰來藥廠
    • 鹽野義製藥株式會社
    • 雅培公司
Product Code: FBI113662

Growth Factors of cephalosporin Market

The global cephalosporin market continues to witness strong momentum, driven by increasing antimicrobial resistance, new product approvals, and rising demand for broad-spectrum antibiotics. In 2024, the market was valued at USD 7.93 billion, supported by high utilization of third- and fourth-generation cephalosporins for treating respiratory infections, skin infections, meningitis, and hospital-acquired bacterial diseases. The market is projected to grow to USD 8.32 billion in 2025, reflecting expanding usage across hospitals and outpatient settings. By 2032, the global market is expected to reach USD 12.07 billion, driven by increased AMR cases, accelerated approvals for advanced formulations, and investments in next-generation antibiotic research.

In 2024, North America dominated the market with a 46.78% share, owing to high infection prevalence, robust hospital infrastructure, and strong adoption of new cephalosporin drugs.

Market Drivers

A key driver shaping market growth is the escalating prevalence of antibiotic-resistant bacteria, which has increased demand for new-generation cephalosporins. Pharmaceutical companies such as GSK plc., Pfizer Inc., Sandoz Group AG, and Merck & Co., Inc., are intensifying R&D efforts to introduce innovative therapies capable of combating AMR strains. New approvals such as Basilea Pharmaceutica's ZEVTERA, approved by the U.S. FDA in April 2024, further strengthen market expansion by offering treatment options for bacteremia, ABSSSI, and pneumonia across adult and pediatric populations.

Cephalosporins offer fewer side effects, broad-spectrum coverage, and high therapeutic efficacy-features that continue to make them essential in global infectious disease management.

Market Restraints

Despite rising demand, the market faces challenges due to adverse reactions associated with cephalosporin use. Gastrointestinal problems, allergic reactions, and more severe neurotoxic effects have been reported, especially in older adults and those receiving high IV doses. In 2023, the New Zealand MARC highlighted risks including encephalopathy, seizures, and myoclonus associated with intravenous cephalosporins. These concerns may limit prescriptions in at-risk groups, thereby restraining market growth.

Market Opportunities

The emergence of nanoparticle-based drug delivery systems offers significant future potential. Research shows that gold nanoparticles (AuNPs) and silver nanoparticle-based formulations can revive and enhance the potency of older cephalosporin molecules. These nano-antibiotics improve drug efficacy, extend plasma half-life, and offer controlled drug release. Studies published by the NIH in 2023 demonstrated successful conversion of low-efficacy cephalosporins into potent nano-therapeutics, presenting lucrative opportunities for pharmaceutical innovations.

Segmental Analysis

By Generation

The third-generation cephalosporins dominated the market in 2024 due to their ability to treat meningitis, respiratory infections, and various soft-tissue infections. First-generation cephalosporins remain widely used for uncomplicated infections, while second-generation drugs maintain steady demand for respiratory and ENT infections. Meanwhile, fourth and fifth generations address rising AMR challenges and continue to gain traction.

By Route of Administration

The oral route is expected to record strong growth, supported by patient preference for self-administration and new drug approvals such as Fairdeal Corporation's Cefixime 400 mg tablets in 2024.

The parenteral route remains equally crucial, especially for severe infections requiring hospital-based treatments. New IV product launches, including Shionogi's Fetroja in 2023, strengthen this segment.

By Disease Indication

The urinary tract infections (UTI) segment is expected to dominate due to rising incidence of hospital-acquired UTIs and proven effectiveness of various cephalosporin generations in UTI management.

Other major segments-skin & soft tissue infections, respiratory infections, meningitis-also contribute significantly due to high global prevalence and broad clinical applications.

By Distribution Channel

Hospital pharmacies lead the market owing to high prescription volumes and treatment of acute infections requiring cephalosporins. Retail pharmacies follow, supported by wide accessibility and availability of oral formulations. Online pharmacies are growing steadily due to convenience, cost benefits, and increasing digital health adoption.

Regional Outlook

North America

North America generated USD 3.71 billion in 2024, supported by rising MRSA infections, high healthcare spending, and rapid adoption of advanced cephalosporin therapies. The U.S. leads the regional market, backed by continuous R&D investments-such as Roche's USD 50 billion expansion in 2025.

Europe

Europe holds the second-largest share, driven by increased consumption of second- and third-generation cephalosporins and strong antimicrobial stewardship initiatives.

Asia Pacific

The region is projected to witness the fastest CAGR between 2025 and 2032 due to large antibiotic consumption, robust API manufacturing, and strategic acquisitions such as Hasten Biopharmaceutics' 2023 purchase of Rocephin rights in China.

Latin America & Middle East/Africa

These regions show steady growth supported by increasing awareness of AMR, improving healthcare infrastructure, and new regulatory approvals for cephalosporin manufacturing.

Conclusion

Growing from USD 7.93 billion in 2024 to USD 12.07 billion by 2032, the global cephalosporin market is set for robust expansion. Rising AMR cases, advanced product launches, nano-antibiotic innovations, and strong government initiatives will continue to drive long-term demand across all major regions.

Segmentation

By Generation

  • First Generation
  • Second Generation
  • Third Generation
  • Fourth Generation
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Disease Indications

  • Urinary Tract Infections
  • Skin & Soft Tissue infection
  • Respiratory Infections
  • Meningitis
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • U.S.
    • Canada
  • Europe (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Overview of Antimicrobial Treatment Guidelines
  • 4.3. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. New Product Launches, By Key Players

5. Global Cephalosporin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Generation
    • 5.1.1. First Generation
    • 5.1.2. Second Generation
    • 5.1.3. Third Generation
    • 5.1.4. Fourth Generation
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Urinary Tract Infections
    • 5.3.2. Skin & Soft Tissue Infections
    • 5.3.3. Respiratory Infections
    • 5.3.4. Meningitis
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cephalosporin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Generation
    • 6.1.1. First Generation
    • 6.1.2. Second Generation
    • 6.1.3. Third Generation
    • 6.1.4. Fourth Generation
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Urinary Tract Infections
    • 6.3.2. Skin & Soft Tissue Infections
    • 6.3.3. Respiratory Infections
    • 6.3.4. Meningitis
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cephalosporin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Generation
    • 7.1.1. First Generation
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Fourth Generation
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Urinary Tract Infections
    • 7.3.2. Skin & Soft Tissue Infections
    • 7.3.3. Respiratory Infections
    • 7.3.4. Meningitis
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cephalosporin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Generation
    • 8.1.1. First Generation
    • 8.1.2. Second Generation
    • 8.1.3. Third Generation
    • 8.1.4. Fourth Generation
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Urinary Tract Infections
    • 8.3.2. Skin & Soft Tissue Infections
    • 8.3.3. Respiratory Infections
    • 8.3.4. Meningitis
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cephalosporin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Generation
    • 9.1.1. First Generation
    • 9.1.2. Second Generation
    • 9.1.3. Third Generation
    • 9.1.4. Fourth Generation
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Urinary Tract Infections
    • 9.3.2. Skin & Soft Tissue Infections
    • 9.3.3. Respiratory Infections
    • 9.3.4. Meningitis
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cephalosporin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Generation
    • 10.1.1. First Generation
    • 10.1.2. Second Generation
    • 10.1.3. Third Generation
    • 10.1.4. Fourth Generation
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Urinary Tract Infections
    • 10.3.2. Skin & Soft Tissue Infections
    • 10.3.3. Respiratory Infections
    • 10.3.4. Meningitis
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sandoz Group AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.,
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AbbVie Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bayer AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Astellas Pharma Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Shionogi & Co., Ltd
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Abbott
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 2: Global Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
  • Table 4: Global Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global Cephalosporin Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 7: North America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 8: North America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
  • Table 9: North America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America Cephalosporin Market Revenue (USD billion) Forecast, by Country, 2019-2032
  • Table 11: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 12: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 13: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
  • Table 14: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
  • Table 16: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 17: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 18: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
  • Table 19: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
  • Table 21: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 22: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
  • Table 24: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 25: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
  • Table 26: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 27: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 28: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
  • Table 29: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032

List of Figures

  • Figure 1: Global Cephalosporin Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Cephalosporin Market Value Share (%), by Generation, 2024 & 2032
  • Figure 3: Global Cephalosporin Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Cephalosporin Market Value Share (%), by Disease Indication, 2024 & 2032
  • Figure 5: Global Cephalosporin Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Cephalosporin Market Value Share (%), by Region, 2024 & 2032
  • Figure 7: North America Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 8: North America Cephalosporin Market Value Share (%), by Generation, 2024
  • Figure 9: North America Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 10: North America Cephalosporin Market Value Share (%), by Route of Administration, 2024
  • Figure 11: North America Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 12: North America Cephalosporin Market Value Share (%), by Disease Indication, 2024
  • Figure 13: North America Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Cephalosporin Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Cephalosporin Market Value (USD billion), by Country, 2024 & 2032
  • Figure 16: North America Cephalosporin Market Value Share (%), by Country, 2024
  • Figure 17: Europe Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 18: Europe Cephalosporin Market Value Share (%), by Generation, 2024
  • Figure 19: Europe Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 20: Europe Cephalosporin Market Value Share (%), by Route of Administration, 2024
  • Figure 21: Europe Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 22: Europe Cephalosporin Market Value Share (%), by Disease Indication, 2024
  • Figure 23: Europe Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Cephalosporin Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
  • Figure 26: Europe Cephalosporin Market Value Share (%), by Country/Sub-Region, 2024
  • Figure 27: Asia Pacific Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 28: Asia Pacific Cephalosporin Market Value Share (%), by Generation, 2024
  • Figure 29: Asia Pacific Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 30: Asia Pacific Cephalosporin Market Value Share (%), by Route of Administration, 2024
  • Figure 31: Asia Pacific Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 32: Asia Pacific Cephalosporin Market Value Share (%), by Disease Indication, 2024
  • Figure 33: Asia Pacific Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Cephalosporin Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
  • Figure 36: Asia Pacific Cephalosporin Market Value Share (%), by Country/Sub-Region, 2024
  • Figure 37: Latin America Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 38: Latin America Cephalosporin Market Value Share (%), by Generation, 2024
  • Figure 39: Latin America Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 40: Latin America Cephalosporin Market Value Share (%), by Route of Administration, 2024
  • Figure 41: Latin America Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 42: Latin America Cephalosporin Market Value Share (%), by Disease Indication, 2024
  • Figure 43: Latin America Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Cephalosporin Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
  • Figure 46: Latin America Cephalosporin Market Value Share (%), by Country/Sub-Region, 2024
  • Figure 47: Middle East & Africa Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 48: Middle East & Africa Cephalosporin Market Value Share (%), by Generation, 2024
  • Figure 49: Middle East & Africa Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 50: Middle East & Africa Cephalosporin Market Value Share (%), by Route of Administration, 2024
  • Figure 51: Middle East & Africa Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 52: Middle East & Africa Cephalosporin Market Value Share (%), by Disease Indication, 2024
  • Figure 53: Middle East & Africa Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Cephalosporin Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
  • Figure 56: Middle East & Africa Cephalosporin Market Value Share (%), by Country/Sub-Region, 2024
  • Figure 57: Global Cephalosporin Market Share (%), by Company, 2024